Verve Therapeutics, Inc..
VERV.US | Research and experimental development on natural sciences and engineering
Verve Therapeutics, Inc. is a biotechnology company focused on developing gene editing medicines for cardiovascular disease. They are pioneering a new approach to treating coronary artery disease by developing therapies that durably reduce blood lipids, such as cholesterol, through single-course gen...Show More
Better Health for All
0
Verve Therapeutics' entire business is devoted to developing gene editing medicines for cardiovascular disease, aiming to permanently reduce the risk of heart attack and stroke by targeting high LDL cholesterol and lipoprotein(a).
1
In trials, VERVE-102 demonstrated a mean reduction in LDL-C of 53% and a maximum reduction of 69% in the 0.6 mg/kg dose cohort.
2
The company's approach focuses on disease prevention by lowering cumulative LDL-C exposure over a patient's lifetime.
3
However, a Phase 1b clinical trial for VERVE-101 was paused due to a participant experiencing side effects attributed to the delivery vehicle.
4
While VERVE-102 has shown a good safety profile in initial trials with no treatment-related serious adverse events among 14 participants, the prior incident is a notable safety concern.
5
The company acknowledges that current CVD therapies are prohibitively expensive and access is limited in low- and middle-income countries, but there is no evidence of specific pricing strategies or programs to address this for its future products.
6
Similarly, while the company notes rising ASCVD rates in low- and middle-income countries, there is no evidence of specific programs to ensure equitable access for vulnerable populations.
7
Verve provides comprehensive risk disclosures to clinical trial participants, explaining possible benefits and risks, and has identified the cause of side effects in the VERVE-101 trial.
8
The company has received a $60 million upfront payment and equity investment from Eli Lilly for its Lp(a) program, with potential milestones up to $465 million, indicating substantial investment in health innovation.
9
Participant information in clinical trials is stored in a HIPAA-compliant database.
10
Clinical trials are cleared by an Institutional Review Board/Ethics Committee and national health authorities, and participants can withdraw at any time.
11
Fair Money & Economic Opportunity
0
Verve Therapeutics, Inc. is a biotechnology company focused on developing gene editing medicines, not a financial institution.
1
The company does not offer lending, deposit, or other financial services to consumers. Therefore, the KPIs under 'Fair Money & Economic Opportunity,' which are designed to assess financial institutions on aspects like underserved client share, pricing fairness, exploitative fees, inclusion initiatives, data accessibility for financial data, fair lending compliance, wealth-building outcomes, profit reinvestment in community finance, financial literacy initiatives, debt burden ratios, geographic inclusion for financial services, and product simplicity for financial products, are not applicable to its core business model. No evidence was found in the provided articles to score any of these KPIs in the context of financial services.
Fair Pay & Worker Respect
10
Employee engagement, based on an overall employee rating of 3.9 out of 5 stars, is approximately 78%.
1
There are no specific regulatory actions, violations, fines, or compliance issues mentioned in the provided information.
2
The CEO's total compensation for 2024 was $7,442,663, but median employee compensation data is not available, preventing the calculation of a pay ratio.
3
Fair Trade & Ethical Sourcing
0
No data relevant to VERV.US or its Fair Trade & Ethical Sourcing practices was found in the provided articles.
1
All articles focused on Microsoft's policies and performance, explicitly stating no information pertaining to VERV.US.
2
Honest & Fair Business
-10
Verve Therapeutics faces a securities class action lawsuit alleging false and misleading statements regarding its Heart-1 clinical trial and lipid nanoparticle delivery system
1
,
2
,
3
. This raises concerns about transparency and disclosure. However, the company has a confidential and anonymous financial concern hotline for complaints related to accounting and auditing matters, as required by the SEC
4
. There is no available evidence regarding regulatory fines, transparency index scores, financial restatements, audit coverage, ESG controversy index, complaint resolution time, board independence, anti-corruption policies, or third-party verification. The presence of the hotline is a slightly positive indicator, but the lawsuit and absence of strong positive indicators justify a slightly negative score.
5
,
6
,
7
,
8
,
9
Kind to Animals
-40
Verve Therapeutics Inc. conducts pre-clinical studies on animals, including cynomolgus monkeys and mice, to assess product safety and efficacy.
1
While animal studies were approved by an Institutional Animal Care and Use Committee, no explicit company-wide policy on animal testing or its reduction was found.
2
No War, No Weapons
0
The provided articles contain no information regarding Verve Therapeutics, Inc.'s (VERV.US) involvement in arms manufacturing, military contracts, or conflict facilitation, which are relevant to the 'No War, No Weapons' ethical value. One article pertains to a different company (Media and Games Invest), and the other, while about Verve Therapeutics, Inc., explicitly states it contains no data relevant to the requested metrics.
1
Planet-Friendly Business
0
The provided articles contain specific environmental data and initiatives for "Verve Group SE," an AdTech company with a games business.
1
However, the company being assessed is "VERV.US (Verve Therapeutics, Inc.)," a biotechnology company. Due to this discrepancy, the quantitative data and operational details from the articles cannot be attributed to Verve Therapeutics, Inc. contains only general commitments and expectations, not concrete, scorable facts.
2
Consequently, no specific, verifiable evidence could be found to score any of the KPIs for the company under assessment.
Respect for Cultures & Communities
0
No specific, concrete evidence was found in the provided articles to assess Verve Therapeutics, Inc. against any of the KPIs for the 'Respect for Cultures & Communities' value. The articles primarily focus on the company's mission, clinical trials, and general corporate information, without detailing community engagement, cultural impact protocols, local employment, or related initiatives.
Safe & Smart Tech
0
Verve Therapeutics, Inc. offers excellent user data control, providing residents of California, the EEA, UK, Australia, New Zealand, and Canada with rights such as access, correction, deletion, restriction of processing, objection to processing, and data portability.
1
The company implements good data minimization measures and retains information only as long as necessary for its purpose and as allowed by law.
2
Verve Therapeutics, Inc. complies with applicable data protection laws, including the Department of Justice’s Data Security Program (28 C.F.R. Part 202), CCPA, and GDPR requirements.
3
The company also employs reasonable administrative, technical, and physical safeguards to protect personal information and implements appropriate access controls and procedures to respond to potential security incidents.
4
However, the available evidence does not provide specific details on the scope or frequency of security testing, the strength of authentication methods beyond general access controls, or the effectiveness of vulnerability management.
Zero Waste & Sustainable Products
0
No relevant evidence was found in the provided articles for Verve Therapeutics, Inc. (VERV.US) regarding Zero Waste & Sustainable Products. The articles refer to other distinct companies: Verve Coffee (), Verve Spa (), and Media and Games Invest (MGI) / Verve Group (), which are not the biotechnology company being assessed. explicitly states it contains no relevant information for VERV.US.
1